Compare Bristol-Myers Squibb Co (BMY) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Workiva Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.87 (market cap $129.94B), while Workiva Inc trades at $67.93 (market cap $3.76B). The key difference: Bristol-Myers Squibb Co is far larger — about 34.6× Workiva Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| BMY | WK | |
|---|---|---|
Market Cap | $129.94B | $3.76B |
Sector | Health | Technology |
52-Week High | $65.89 | $93.31 |
52-Week Low | $42.60 | $44.31 |
Enterprise Value | $163.92B | $3.73B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
WK trades at $67.73, up 0.61% today, near its consensus price target of $69. The stock shows bullish technical signals with strong moving average support and recent earnings beats. Revenue grew to $966 million in 2026 with net income turning positive at $47 million, reflecting improved profitability. Positive sentiment is driven by AI product launches and consistent earnings outperformance.
Outlook remains positive given earnings momentum and AI innovation, but high valuation multiples pose risks. Investors face elevated P/E and EV/EBITDA ratios, requiring sustained growth to justify premiums. Competitive pressures and execution on AI initiatives are key to maintaining upward trajectory amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
